Skip to search formSkip to main contentSkip to account menu

LCI699

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Specific Aldosterone Synthase Inhibition: A Potential Improvement Over Mineralocorticoid Receptor Antagonism?
See related article, pp 189–196 We have come to appreciate the many physiological and pathophysiological functions of adrenal… 
2015
2015
Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
Review
2014
Review
2014
Molecular basis of pharmacological therapy in Cushing’s disease
Abstract Cushing’s disease (CD) is a severe endocrine condition caused by an adrenocorticotropin (ACTH)-producing pituitary… 
2013
2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy
Context: We describe the clinical investigation of the first generation aldosterone synthase inhibitor, LCI699, in patients with… 
Review
2013
Review
2013
Recent Developments in Drug Therapy for Cushing’s Disease
Cushing’s disease (CD) is a rare endocrine disorder that is caused by an adrenocorticotropin (ACTH)-producing pituitary adenoma… 
Review
2012
Review
2012
New prospects for drug treatment in Cushing disease.
2011
2011
Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism
2011
2011
Aldosterone Synthase Inhibition: A Promising Beginning
We report the first administration of an orally active aldosterone synthase inhibitor, LCI699, to 14 patients with primary… 
2010
2010
BLOCKADE OF ALDOSTERONE PRODUCTION AS A NOVEL APPROACH TO THE MANAGEMENT OF HIGH BLOOD PRESSURE: EFFICACY AND TOLERABILITY OF THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN PATIENTS WITH STAGE 1-2…
2010
2010
HORMONAL EFFECTS OF THE NEW DIRECT ALDOSTERONE SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM: 5C.06
Objective: Aldosterone synthase inhibition with LCI699 is a new therapeutic option aimed at decreasing hormone concentrations in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)